Adaptive Biotechnologies announces the launch of clonoSEQ® to assess minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA)

Adaptive Biotechnologies announces the launch of clonoSEQ® to assess minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA)

clonoSEQ is the first and only Medicare-covered DLBCL MRD test across all lines of therapy, treatment regimens, and time points Adaptive now accepts blood samples from DLBCL patients in ctDNA-stabilizing Streck® tubes SEATTLE, December 01, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of … Read more

Aquestive Therapeutics Announces Publication of Crossover Study of Dietary Effect of Diazepam Nasal Spray in Epilepsy

Aquestive Therapeutics Announces Publication of Crossover Study of Dietary Effect of Diazepam Nasal Spray in Epilepsy

Peer-reviewed data indicate that food significantly decreases and delays the absorption of diazepam dosed via nasal spray WARREN, NJ, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company that advances current standards of care to solve patient problems by simplifying delivery methods complexes, announced today the publication of a pharmacokinetic … Read more

JBM Healthcare Announces Interim Results for Fiscal Year 2023

JBM Healthcare Announces Interim Results for Fiscal Year 2023

HONG KONG, November 25, 2022 – (ACN Newswire) – – JBM (medical care) limited (“JBM Health” or the “Group”; Stock Code: 2161), a leading marketer and distributor of brand name healthcare products in Hong Kongtoday announced the Group’s intermediate results for the semester ended September 30, 2022 (the “Reporting Period”). KEY POINTS — Period-over-period revenue … Read more

BioSenic – Transparency notifications received from Francois Rieger, Veronique Pomi, Capital Grand Est FA DIESE 3 and CPH Banque

BioSenic – Transparency notifications received from Francois Rieger, Veronique Pomi, Capital Grand Est FA DIESE 3 and CPH Banque

BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and function/organ repair, announces today that it has received transparency notifications from François Rieger, veronique pomiGreat East of the capital, FA DIES 3 and CPH Bank. Details of the notices are below and can be … Read more

Terminated lease after ‘robbery’ by landlord, who was searching tenant

Terminated lease after ‘robbery’ by landlord, who was searching tenant

A landlord filmed his tenant, resulting in a “robbery.” Photo/Getty Images After a landlord hit the record button on his mobile phone and began filming his “aggressive” tenant, the tenant slapped the woman’s hand in an attempt to push the phone away from her face. But the owner later claimed that the “attack” was so … Read more

Patient suffers from voice problems after consenting to surgery while under the influence of sedation

Patient suffers from voice problems after consenting to surgery while under the influence of sedation

A kapa haka enthusiast says she lost her mana after suffering ongoing voice problems due to surgery she agreed to while under sedation. Photo / NZME A passionate kapa haka performer who has ongoing voice problems due to surgery she agreed to while under sedation, says she has lost her mana. The woman was treated … Read more

PAXMAN publishes its interim report for the third quarter of 2022

PAXMAN publishes its interim report for the third quarter of 2022

Total Group sales amounted to MSEK 41.3 (23.3) in the third quarter of the year, with an EBITDA of MSEK 5.6 (-1.3). Net income was MSEK 4.7 (-5.2) in the third quarter and earnings per share were 0.24 (-0.3) SEK. Cash flow before financing activities was -14.3 (-6.1) MSEK in the third quarter of the … Read more

COVID-19 Antigen Home Tests: Take Steps to Reduce the Risk of False Negative Results: FDA Safety Statement

COVID-19 Antigen Home Tests: Take Steps to Reduce the Risk of False Negative Results: FDA Safety Statement

November 17, 2022 Update: The FDA took additional action related to the need for retesting following a negative COVID-19 test result on COVID-19 antigen tests: it revised the emergency use authorizations (EUAs) of all tests of COVID-19 Antigen Authorized on November 1, 2022. For more details, see FDA Actions down. Publication date: August 11, 2022 … Read more

COVID-19 Antigen Home Tests: Take Steps to Reduce the Risk of False Negative Results: FDA Safety Statement

COVID-19 Antigen Home Tests: Take Steps to Reduce the Risk of False Negative Results: FDA Safety Statement

November 17, 2022 Update: The FDA took additional action related to the need for retesting following a negative COVID-19 test result on COVID-19 antigen tests: it revised the emergency use authorizations (EUAs) of all tests of COVID-19 Antigen Authorized on November 1, 2022. For more details, see FDA Actions down. Publication date: August 11, 2022 … Read more

COVID-19 Antigen Home Tests: Take Steps to Reduce the Risk of False Negative Results: FDA Safety Statement

COVID-19 Antigen Home Tests: Take Steps to Reduce the Risk of False Negative Results: FDA Safety Statement

November 17, 2022 Update: The FDA took additional action related to the need for retesting following a negative COVID-19 test result on COVID-19 antigen tests: it revised the emergency use authorizations (EUAs) of all tests of COVID-19 Antigen Authorized on November 1, 2022. For more details, see FDA Actions down. Publication date: August 11, 2022 … Read more